Chelsea Hutchinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chelsea Hutchinson has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
- Paul D. Piehowski
Pacific Northwest National Laboratory
28 shared publications - Joshua R. Hansen
Pacific Northwest National Laboratory
27 shared publications - Marina A. Gritsenko
Pacific Northwest National Laboratory
27 shared publications - Karin D. Rodland
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, USA
26 shared publications - Sara J. C. Gosline
Pacific Northwest National Laboratory
26 shared publications - Alisa Damnernsawad
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
25 shared publications
Latest Publications
- 19 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (21) , 2627-2642
NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib
Although the FLT3 inhibitor gilteritinib is initially effective in patients with FLT3-mutated acute myeloid leukemia (AML), patients invariably relapse within months of treatment. Gilteritinib resistance is commonly driven by the emergence of NRAS mutations and a shift toward a more monocytic cell state. We hypothesized that directly targeting and depleting NRAS protein would reverse these adaptive differentiation changes and restore therapeutic sensitivity. To test this, we used a mutation-agnostic antisense oligonucleotide (ASO) to selectively knock down NRAS expression across gilteritinib-resistant AML cell lines, in vivo cell line–derived xenografts, and primary patient samples. NRAS ASO successfully resensitized gilteritinib-resistant cells with multiple distinct NRAS mutations, displaying superior efficacy compared with downstream MEK inhibition. This therapeutic efficacy was independent of NRAS-mutant variant allele frequency, suggesting that wild-type NRAS may also contribute to resistance. Comprehensive multiomics profiling (transcriptomics, proteomics, and phosphoproteomics) revealed that NRAS knockdown consistently reversed the monocytic phenotype, shifting cells back toward a more primitive cell state. Monocytic differentiation and NRAS mutations are established drivers of resistance to diverse targeted regimens in AML, including FLT3, IDH, and BCL2 inhibitors. Therefore, we also tested venetoclax-resistant primary cells with NRAS mutations. Resistant cells were resensitized to venetoclax after NRAS knockdown, suggesting that NRAS knockdown may be more broadly applicable for overcoming monocytic cell state and drug resistance in AML.
- 19 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (21) , 2627-2642
NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib
Although the FLT3 inhibitor gilteritinib is initially effective in patients with FLT3-mutated acute myeloid leukemia (AML), patients invariably relapse within months of treatment. Gilteritinib resistance is commonly driven by the emergence of NRAS mutations and a shift toward a more monocytic cell state. We hypothesized that directly targeting and depleting NRAS protein would reverse these adaptive differentiation changes and restore therapeutic sensitivity. To test this, we used a mutation-agnostic antisense oligonucleotide (ASO) to selectively knock down NRAS expression across gilteritinib-resistant AML cell lines, in vivo cell line–derived xenografts, and primary patient samples. NRAS ASO successfully resensitized gilteritinib-resistant cells with multiple distinct NRAS mutations, displaying superior efficacy compared with downstream MEK inhibition. This therapeutic efficacy was independent of NRAS-mutant variant allele frequency, suggesting that wild-type NRAS may also contribute to resistance. Comprehensive multiomics profiling (transcriptomics, proteomics, and phosphoproteomics) revealed that NRAS knockdown consistently reversed the monocytic phenotype, shifting cells back toward a more primitive cell state. Monocytic differentiation and NRAS mutations are established drivers of resistance to diverse targeted regimens in AML, including FLT3, IDH, and BCL2 inhibitors. Therefore, we also tested venetoclax-resistant primary cells with NRAS mutations. Resistant cells were resensitized to venetoclax after NRAS knockdown, suggesting that NRAS knockdown may be more broadly applicable for overcoming monocytic cell state and drug resistance in AML.
- Open Access
- 12 September 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 5026-5045
Human Coronavirus-229E Hijacks Key Host-Cell RNA-Processing Complexes for Replication
The recent rise in zoonotic coronavirus outbreaks underscores the urgency to understand virus-host interactions to develop potent antiviral therapeutics. Systems biology approaches, particularly proteomics, have been invaluable in providing a global overview of such interactions. However, these conventional approaches rely on measuring protein abundance changes that do not capture all molecular changes associated with altered regulatory pathways. In this study, we employed a high-throughput structural proteomics approach called limited proteolysis-based mass spectrometry (LiP-MS) to capture protein conformational changes, which we demonstrate are better proxies for functional alterations. We applied this tool to profile the molecular landscape of different human lung cells following human coronavirus-229E (HCoV-229E) infection. We found that HCoV-229E uses a multipronged approach to hijack key RNA-processing pathways and assemblies as part of a host-shutoff strategy to achieve effective replication. We confirm our results with structural data derived from changes in the assemblies after infection. We go on to show that modulation of two of these assemblies, the Nop56-associated pre-rRNA complex and the spliceosome C-complex, can attenuate HCoV-229E replication, indicating that we have identified viable host-cell therapeutic targets with potential to provide broad efficacy against coronavirus infection.
- 12 September 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 5026-5045
Open AccessHuman Coronavirus-229E Hijacks Key Host-Cell RNA-Processing Complexes for Replication
The recent rise in zoonotic coronavirus outbreaks underscores the urgency to understand virus-host interactions to develop potent antiviral therapeutics. Systems biology approaches, particularly proteomics, have been invaluable in providing a global overview of such interactions. However, these conventional approaches rely on measuring protein abundance changes that do not capture all molecular changes associated with altered regulatory pathways. In this study, we employed a high-throughput structural proteomics approach called limited proteolysis-based mass spectrometry (LiP-MS) to capture protein conformational changes, which we demonstrate are better proxies for functional alterations. We applied this tool to profile the molecular landscape of different human lung cells following human coronavirus-229E (HCoV-229E) infection. We found that HCoV-229E uses a multipronged approach to hijack key RNA-processing pathways and assemblies as part of a host-shutoff strategy to achieve effective replication. We confirm our results with structural data derived from changes in the assemblies after infection. We go on to show that modulation of two of these assemblies, the Nop56-associated pre-rRNA complex and the spliceosome C-complex, can attenuate HCoV-229E replication, indicating that we have identified viable host-cell therapeutic targets with potential to provide broad efficacy against coronavirus infection.
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supp Table S3 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
RNA-seq gene list and pathway correlation with drug resistance
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Table S3 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
RNA-seq gene list and pathway correlation with drug resistance
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S8 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
GSEA analysis from trametinib-sensitive and resistant cells
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S8 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
GSEA analysis from trametinib-sensitive and resistant cells
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Suppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Suppl Table S5 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S7 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Phosphopeptides identified by trametinib and CCL2 treatments using a KSEA analysis
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Suppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Table S10 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
CRISPR pathway enrichment analysis